Detalles de la búsqueda
1.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat;
201(2): 151-159, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338729
2.
Incidence of complications associated to bile duct stents, in patients with advanced cancer: a single-center experience.
Support Care Cancer;
30(5): 4373-4378, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094137
3.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Breast Cancer Res Treat;
184(2): 469-479, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32876911
4.
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Breast Cancer Res Treat;
177(1): 53-60, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31127467
5.
Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.
Br J Cancer;
115(3): 322-31, 2016 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27404455
6.
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.
BMC Cancer;
16(1): 660, 2016 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27542890
7.
Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program.
Breast Cancer Res Treat;
149(1): 237-44, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25503778
8.
An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
Anticancer Drugs;
25(9): 992-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24892723
9.
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
J Exp Clin Cancer Res;
43(1): 10, 2024 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38167224
10.
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
JAMA Netw Open;
7(4): e247811, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38648056
11.
Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Breast Cancer Res Treat;
140(2): 385-95, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23868189
12.
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Clin Transl Oncol;
25(4): 941-958, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417083
13.
Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells.
Hum Pathol;
139: 91-105, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517596
14.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Neuro Oncol;
25(1): 157-166, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639825
15.
Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
Breast Cancer Res Treat;
133(3): 1159-67, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22434523
16.
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Anticancer Drugs;
23(2): 239-46, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22112931
17.
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Nat Cancer;
3(3): 355-370, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35301507
18.
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Breast Cancer Res Treat;
125(3): 869-78, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20665105
19.
Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.
Anticancer Drugs;
22(3): 283-9, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21150776
20.
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Clin Cancer Res;
27(18): 5096-5108, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34385295